Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
rFIX · 2 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| rFIX | DRUG | - |
| rFIX-R | DRUG | - |
Inclusion Criteria: * Hemophilia B (FIX:C less than 2%) * Previous treatment of at least 150 exposure days using any FIX product * 12 years of age and older Exclusion Criteria: * The patient has a currently detectable factor IX inhibitor or a history of inhibitors. (A family history of inhibitors...
rFIX is a recombinant factor IX therapy used for the treatment of Hemophilia B, a bleeding disorder caused by a deficiency of clotting factor IX. It is being developed by Pfizer, Inc. and is currently in Phase 3 clinical development, meaning it is investigational and not yet approved.
rFIX is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 3 clinical trials for the treatment of Hemophilia B.
rFIX is in Phase 3 clinical development for the treatment of Hemophilia B. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 3 trials have been completed, with a total enrollment of 23 participants in one of the studies.
rFIX has been studied in two completed Phase 3 clinical trials. The first, NCT00093171, evaluated rFIX (BeneFIX) in Hemophilia B with 23 participants aged 12 years and older in the United States. The second, NCT00093210, evaluated recombinant human factor IX (BeneFIX) and a new formulation (rFIX-R) in moderate to severe Hemophilia B.
Yes, rFIX is also known as BeneFIX. The clinical trials NCT00093171 and NCT00093210 refer to rFIX as BeneFIX, and the second trial also evaluates a new formulation called rFIX-R. Both are recombinant factor IX products for Hemophilia B.